Poseida Therapeutics, Inc (PSTX)

Etorro trading 970x250
Poseida Therapeutics, Inc (PSTX) Logo

About Poseida Therapeutics, Inc

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat relapsed/refractory multiple myeloma patients; P-MUC1C-ALLO1, an allogeneic CAR-T product candidate for multiple solid tumor indications; and P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. It is also developing P-OTC-101, a liver-directed gene therapy for the treatment of ornithine transcarbamylase; and P-MMUT-101, a liver-directed gene therapy for the treatment of methylmalonic acidemia. In addition, the company is developing a portfolio of allogeneic dual CAR product candidates. The company was incorporated in 2014 and is headquartered in San Diego, California. Address: 9390 Towne Centre Drive, San Diego, CA, United States, 92121

Poseida Therapeutics, Inc News and around…

Latest news about Poseida Therapeutics, Inc (PSTX) common stock and company :

Wall Street Analysts Think Poseida Therapeutics, Inc. (PSTX) Could Surge 277%: Read This Before Placing a Bet
24 Nov, 2021 Yahoo! Finance

The average of price targets set by Wall Street analysts indicates a potential upside of 276.7% in Poseida Therapeutics, Inc. (PSTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Land This Bargain Even Cheaper Than Chief Operating Officer Ingalls Did
22 Nov, 2021 FinancialContent

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on November 17, Poseida Therapeutics Inc's Chief Operating Officer, Kerry D..

4 Stocks Insiders Are Buying
19 Nov, 2021 FinancialContent

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. ...

Poseida Therapeutics Insider Sold Over $135K In Company Stock
11 Nov, 2021 Yahoo! Finance

Eric Ostertag, Insider at Poseida Therapeutics (NASDAQ:PSTX), made a large insider sell on November 8, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Ostertag sold 18,924 shares of Poseida Therapeutics at a price of $7.09. The total transaction amounted to $134,171. Ostertag still owns a total of 3,519,151 shares of Poseida Therapeutics worth, $24,959,930. Poseida Therapeutics shares are trading up 1.03% at $7.

Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021
09 Nov, 2021 Yahoo! Finance

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the third quarter ended September 30, 2021.

Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer 2021 Annual Meeting
09 Nov, 2021 Yahoo! Finance

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the upcoming presentation of preclinical data highlighting P-BCMA-ALLO1 for the treatment of relapsed/refractory multiple myeloma and P-MUC1C-ALLO1 for the treatment of multiple solid tumor indications at the Society for Immunotherapy of Cancer 2021 Annual Meeting (SITC

Wall Street Analysts Predict a 281% Upside in Poseida Therapeutics, Inc. (PSTX): Here's What You Should Know
08 Nov, 2021 Yahoo! Finance

The mean of analysts' price targets for Poseida Therapeutics, Inc. (PSTX) points to a 281% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences
03 Nov, 2021 Yahoo! Finance

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company will participate in the following upcoming virtual investor conferences:

IBBQ's Underlying Holdings Imply 33% Gain Potential
25 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Nasdaq Biotechnology ETF (IBBQ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $33.09 per unit.

Poseida Therapeutics Announces Leadership Appointments
13 Oct, 2021 Yahoo! Finance

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced appointments to new roles on its executive leadership team. Effective immediately, Johanna Mylet, C.P.A., will serve as Chief Financial Officer; Devon Shedlock, Ph.D., will become Chief Scientific Officer, Cell Therapies; Kristin Martin will assume the role of Chief Peo

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

A new deal with Takeda could mean up to $3.6 billion in milestone payments for Poseida Therapeutics
12 Oct, 2021 Yahoo! Finance

Shares of Poseida Therapeutics Inc. were up 9.6% in premarket trading on Tuesday after the company said it signed a research and licensing agreement with Takeda Pharmaceutical Co. Ltd. to study and commercialize up to eight gene therapies. Takeda will pay Poseida $45 million upfront and could pay up to $125 million in preclinical milestones. If all milestones for six therapies are met, Takeda will pay $2.7 billion to Poseida; and if all milestones are met for the eight therapies, then Takeda wil

Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies
12 Oct, 2021 Yahoo! Finance

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it has entered into a research collaboration and exclusive license agreement with Takeda Pharmaceutical Company Limited ("Takeda") to utilize Poseida's piggyBac, Cas-CLOVER, biodegradable DNA and RNA nanoparticle delivery technology and other proprietary genetic en

Notable Poseida Therapeutics Insider Makes $140K Sale
06 Oct, 2021 Yahoo! Finance

Eric Ostertag, Chief Executive Officer at Poseida Therapeutics (NASDAQ:PSTX), made a large insider sell on October 1, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Ostertag sold 20,029 shares of Poseida Therapeutics at a price of $7.02. The total transaction amounted to $140,604. Following the transaction, Ostertag still owns 3,528,202 shares of the company, worth $23,109,723. Poseida Therapeutics shares are t

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
05 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual Meeting
01 Oct, 2021 Yahoo! Finance

Poseida Therapeutics, Inc. (Nadsaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced it will give two virtual poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, being held in Washington, D.C., and virtually November 10-14, 2021.

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
30 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
29 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

How The Parts Add Up: VHT Headed For $289
23 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Health Care ETF (VHT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $289.42 per unit.

The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
23 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
21 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Chief Executive Officer Of Poseida Therapeutics Trades $335.44 Thousand In Company Stock
16 Sep, 2021 Yahoo! Finance

Eric Ostertag, Chief Executive Officer at Poseida Therapeutics (NASDAQ:PSTX), made a large buy and sell of company shares on September 14, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission reports that on September 14, Eric Ostertag bought 21,281 Poseida Therapeutics shares at prices ranging from $1.17 to $9.15 per share, for a total of $172,729. They then sold their shares on the same day in the open market at a price of $8.14 to rais

What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?
02 Sep, 2021 Yahoo! Finance

Every investor in Poseida Therapeutics, Inc. ( NASDAQ:PSTX ) should be aware of the most powerful shareholder groups...

55 Biggest Movers From Yesterday
01 Sep, 2021 FinancialContent

Gainers Unico American Corporation (NASDAQ: UNAM) shares gained 59% to close at $4.15 on Tuesday. Elys Game Technology, Corp. ...

Poseida's Solid Tumor CAR-T Candidate Data Fails To Impress Investors
31 Aug, 2021 FinancialContent

The death of a patient in a solid tumor trial hitPoseida Therapeutics Inc(NASDAQ: PSTX) hard last August, but since then, ...

33 Stocks Moving In Tuesday's Mid-Day Session
31 Aug, 2021 FinancialContent

Gainers AC Immune SA (NASDAQ: ACIU) shares jumped 68.4% to $11.77. AC Immune and its collaborating partner Genentech, part of ...

Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit
31 Aug, 2021 Yahoo! Finance

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced preliminary results from its Phase 1 clinical trial of P-PSMA-101, the Company's solid tumor autologous CAR-T product candidate to treat patients with metastatic castrate-resistant prostate cancer (mCRPC). These data will be presented at the 6th Annual CAR-TCR Summit vi

12 Health Care Stocks Moving In Monday's Intraday Session
30 Aug, 2021 FinancialContent

Gainers Valneva (NASDAQ:VALN) stock moved upwards by 29.61% to $49.9 during Monday's regular session. Valneva's ...

Poseida's Fully Allogeneic CAR-T Product Enters Human Trial For Multiple Myeloma
30 Aug, 2021 FinancialContent

TheFDA has clearedPoseida Therapeutics Inc(NASDAQ: PSTX) Investigational New Drug (IND) application for ...

Poseida Therapeutics, Inc (PSTX) is a NASDAQ Common Stock listed in , ,

970x250